TP53 and myelodysplastic syndrome: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) harboring TP53 mutations or deletions are distinct clinicogenomic entities (Arber et al, 2022; Döhner et al, 2022; Khoury et al, 2022).